TY - JOUR T1 - Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives JF - Cancer Biology & Medicine JO - Cancer Biology & Medicine SP - 1649 LP - 1661 DO - 10.20892/j.issn.2095-3941.2022.0489 VL - 19 IS - 12 AU - Rilan Bai AU - Wenqian Li AU - Jiuwei Cui Y1 - 2022/12/15 UR - http://www.cancerbiomed.org/content/19/12/1649.abstract N2 - Neuroendocrine neoplasms (NENs) are a highly heterogeneous class of tumors arising from neuroendocrine cells and peptidergic neurons. After failure of first-line treatment, patients have poor prognosis and limited treatment options. Immune checkpoint inhibitors (ICIs) may be a powerful means of increasing therapeutic efficacy for such patients, but ICIs alone have low response rates and short disease control durations in most NENs and may be effective for only a portion of the population. ICIs combined with other immunotherapies, targeted therapies, or cytotoxic drugs have achieved some efficacy in patients with NENs and are worthy of further exploration to assess their benefits to the population. In addition, accumulating experimental and clinical evidence supports that the interaction between neuroendocrine and immune systems is essential to maintain homeostasis, and assessment of this broad neuroendocrine-immune correlation is essential for NEN treatment. In this review, we summarize the immune microenvironment characteristics, advances in immunotherapy, predictive biomarkers of ICI efficacy for NENs, and the effects of common endocrine hormones on the immune system, highlighting possible new application areas for this promising treatment in neglected NENs. ER -